ACT BETAHISTINE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

BETAHISTINE HYDROCHLORIDE

Disponible desde:

ACTAVIS PHARMA COMPANY

Código ATC:

N07CA01

Designación común internacional (DCI):

BETAHISTINE

Dosis:

16MG

formulario farmacéutico:

TABLET

Composición:

BETAHISTINE HYDROCHLORIDE 16MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0103555003; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2018-06-12

Ficha técnica

_ _
_Product Monograph - _
ACT
_ _
BETAHISTINE
_ _
_Page 1 of 21_
PRODUCT MONOGRAPH
PR ACT BETAHISTINE
Betahistine dihydrochloride tablets, BP
16 MG AND 24 MG
ANTI-VERTIGO AGENT
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
November 6, 2017
Submission Control No.: 210611
_ _
_Product Monograph - _
ACT
_ _
BETAHISTINE
_ _
_Page 2 of 21_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
................................................................................12
PHARMACEUTICAL INFORMATION
..........................................................................12
CLINICAL TRIALS
......................................................................................